Pituistat
Loading...Pituistat Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
For temporary relief of mental sluggishness, confusion, weakness, lethargy, thirst and frequent urination.**
**These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Pituistat Manufacturers
-
Energique, Inc.
![Pituistat (Aralia Quinquefolia, Ginkgo Biloba, Arsenicum Iodatum, Avena Sativa, Baryta Carbonica, Phosphorus, Silicea, Thyroidinum (Suis), Aluminum, Antimony, Barium, Beryllium, Bismuth, Boron, Bromine, Calcium, Carbon, Cerium, Cesium, Chloride, Chromium, Cobalt, Copper, Dysprosium, Erbium, Europium, Fluoride, Gadolinium, Gallium, Germanium, Gold, Hafnium, Holmium, Indium, Iodine, Iridium, Iron, Lanthanum, Lithium, Lutetium, Magnesium, Manganese, Molybdenum, Neodymium, Nickel, Niobium, Osmium, Palladium) Liquid [Energique, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Pituistat | Sebela Pharmaceuticals Inc.
2.1 Paget’s Disease of BoneThe recommended dose of Miacalcin injection for treatment of symptomatic Paget's disease of bone is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly.
2.2 HypercalcemiaThe recommended starting dose of Miacalcin injection for early treatment of hypercalcemia is 4 International Units/kg body weight every 12 hours by subcutaneous or intramuscular injection. If the response to this dose is not satisfactory after one or two days, the dose may be increased to 8 International Units/kg every 12 hours. If the response remains unsatisfactory after two more days, the dose may be further increased to a maximum of 8 International Units/kg every 6 hours.
2.3 Postmenopausal OsteoporosisThe recommended dose of Miacalcin injection for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly. The minimum effective dose of Miacalcin injection for the prevention of vertebral bone mineral density loss has not been established.
2.4 Preparation and AdministrationVisually inspect Miacalcin vials. Miacalcin injection is a clear, colorless, solution. If the solution is not clear and colorless, or contains any particles, or if the vial is damaged, do not administer the solution. If the volume of Miacalcin injection to be injected exceeds 2 mL, intramuscular injection is preferable and the total dose should be distributed across multiple sites of injection. Instruct patients to use sterile injection technique when administering Miacalcin injection, and to dispose of needles properly.
2.5 Recommendations for Calcium and Vitamin D SupplementationPatients who use Miacalcin injection for treatment of postmenopausal osteoporosis should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).
Login To Your Free Account